Literature DB >> 19527090

Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19527090     DOI: 10.1586/erp.09.25

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


× No keyword cloud information.
  1 in total

1.  Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.

Authors:  Jay M Margolis; Robert Fowler; Barbara H Johnson; Cheryl A Kassed; Kristijan Kahler
Journal:  BMC Neurol       Date:  2011-10-06       Impact factor: 2.474

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.